EFFECTS OF ORAL TESTOSTERONE UNDECANOATE ON GROWTH, BODY-COMPOSITION, STRENGTH AND ENERGY-EXPENDITURE OF ADOLESCENT BOYS

被引:33
作者
GREGORY, JW
GREENE, SA
THOMPSON, J
SCRIMGEOUR, CM
RENNIE, MJ
机构
[1] UNIV DUNDEE, DEPT CHILD HLTH, DUNDEE DD1 4HN, SCOTLAND
[2] UNIV DUNDEE, DEPT ANAT & PHYSIOL, DUNDEE DD1 4HN, SCOTLAND
基金
英国惠康基金;
关键词
D O I
10.1111/j.1365-2265.1992.tb02312.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE We determined the effect of 3 months of daily, 40 mg oral testosterone undecanoate on growth, body composition, hand grip and quadriceps muscle strength, and total free-living daily energy expenditure in boys with constitutionally delayed puberty. DESIGN Double blind, placebo controlled study. PATIENTS Eighteen boys with constitutionally delayed puberty, mean (SD) age 13.2 (1.6) years. MEASUREMENTS Body composition measurements were made by skinfold thickness, bioelectrical impedance and stable isotope dilution ((H2O)-O-18) methods. Energy expenditure was assessed by the doubly-labelled water ((H2O)-H-2-O-18) technique. RESULTS Height velocity increased from 5.4 (0.8) to 8.1 (0.6) cm/year (P < 0.05) in the 3 months after active therapy. Fat-free mass increased more with therapy (2.7 (0.3) kg) over the 6-month study period than with placebo (1.7 (0.4) kg, P < 0.5). Height velocity increases correlated with daily increases in fat-free mass (r = 0.68, P = 0.005) in the study group as a whole. Energy expenditure and muscle strength increased similarly in both groups. Predicted adult height decreased in the group which was treated with testosterone undecanoate. CONCLUSIONS Testosterone undecanoate (40 mg daily for 3 months) significantly increased height velocity and fat-free mass velocities after 6 months but not muscle strength, endurance or total dally energy expenditure.
引用
收藏
页码:207 / 213
页数:7
相关论文
共 46 条
[1]   PATTERNS OF PHYSICAL-ACTIVITY AMONG 11-YEAR-OLD TO 16-YEAR-OLD BRITISH CHILDREN [J].
ARMSTRONG, N ;
BALDING, J ;
GENTLE, P ;
KIRBY, B .
BRITISH MEDICAL JOURNAL, 1990, 301 (6745) :203-205
[2]  
BLACK AE, 1986, HUM NUTR-CLIN NUTR, V40C, P381
[4]   WHICH TESTOSTERONE REPLACEMENT THERAPY [J].
CANTRILL, JA ;
DEWIS, P ;
LARGE, DM ;
NEWMAN, M ;
ANDERSON, DC .
CLINICAL ENDOCRINOLOGY, 1984, 21 (02) :97-107
[5]   HEPATIC ADENOMATA AND ANDROGEN TREATMENT [J].
CARRASCO, D ;
PALLARDO, L ;
PRIETO, M ;
MOLL, JL ;
CRUZ, JM ;
BERENGUER, J .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (02) :316-316
[6]   RANDOMIZED CLINICAL-TRIAL OF TESTOSTERONE REPLACEMENT THERAPY IN HYPOGONADAL MEN [J].
CONWAY, AJ ;
BOYLAN, LM ;
HOWE, C ;
ROSS, G ;
HANDELSMAN, DJ .
INTERNATIONAL JOURNAL OF ANDROLOGY, 1988, 11 (04) :247-264
[7]  
COWARD WA, 1985, EPIDEMIOLOGICAL RES, P126
[8]  
DEAMER WC, 1948, AM J DIS CHILD, V75, P850
[9]   ASSESSMENT OF AMOUNT OF FAT IN HUMAN BODY FROM MEASUREMENTS OF SKINFOLD THICKNESS [J].
DURNIN, JVG ;
RAHAMAN, MM .
BRITISH JOURNAL OF NUTRITION, 1967, 21 (03) :681-+
[10]  
FALK H, 1979, LANCET, V2, P1120